Overview
BIO market data
Price History
BIO price chart
Valuation & Profitability
- P/E (TTM)
- 42.28 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $27.85 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.08 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 8.6% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $236.73 – $362.42 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $9.4B · P/B 1.10 · P/S 3.63.
Company News
RBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $390Benzinga · Aug 7, 2026, 6:34 PM
AI Disruption Reshapes Bioinformatics: Record Investment and Breakthrough Tools Signal a New Era for Drug Discovery and Precision MedicineGlobenewswire Inc · Aug 6, 2026, 3:15 PM
Citigroup Maintains Neutral on Bio-Rad Laboratories, Raises Price Target to $330Benzinga · Aug 5, 2026, 6:54 PM
RBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $370Benzinga · Aug 5, 2026, 3:46 PM
Wells Fargo Maintains Equal-Weight on Bio-Rad Laboratories, Raises Price Target to $330Benzinga · Aug 5, 2026, 3:02 PM
Bio-Rad Starts Restructuring Plan To Enhance Operating Performance; Restructuring Plan Includes Job Cuts, Function Consolidation, And Facility Closures Worldwide; Expects Pre-Tax Charges Of ~$80M - $90M; Restructuring Program Anticipated To Be Completed By End Of FY27Benzinga · Aug 4, 2026, 9:15 PM
Bio-Rad Laboratories Lowers FY2026 Sales Guidance of $2.506B-$2.596B vs $2.567B EstBenzinga · Aug 4, 2026, 8:24 PM
Bio-Rad Laboratories Q2 Adj. EPS $2.62 Beats $1.75 Estimate, Sales $651.000M Beat $623.989M EstimateBenzinga · Aug 4, 2026, 8:16 PM
Blood Transfusion Diagnostics Market Size to Hit USD 8.67 Billion by 2035 as Automated Testing and AI-Driven Blood Safety Solutions Accelerate Growth | SNS InsiderGlobenewswire Inc · Jul 24, 2026, 2:15 PM
Molecular Biology Enzymes, Reagents and Kits Market Size Worth USD 70.85 Billion by 2035 | SNS InsiderGlobenewswire Inc · Jul 3, 2026, 11:15 AM